Sir; Being newt huy, I'm not quite sure if this what you are referring to or need. I've only included the excerpts from the full items that specifically refer to Wyeth. Chronilogical order. W
= = = = =
THE TENNESSEAN (Nashville, Tennessee) 12 December 03 Protherics bites back (Naomi Snyder)
When then 4-year-old Emma Murphy was rushed into a hospital in Tucson last year with a severe rattlesnake bite, the doctor brought in to supervise her care had a special knowledge of her condition.
He had helped develop the antivenin that would save her.
''She was a sick little girl,'' said medical toxicologist John B. Sullivan. ''I've seen a lot of sick kids, and she was one of the few very sick ones I've seen.''
Sullivan pumped her little body with 44 vials of CroFab, a drug manufactured by an English company with U.S. headquarters in Brentwood. A typical adult dose is 10 to 15 vials.
CroFab is the only rattlesnake antivenin on the market in the United States, after competitor Wyeth took its drug off the market last year. Sales have taken off for the CroFab drug, which company officials attribute to a growing awareness in the medical community about the snakebite antidote.
THE COURIER (Houma, Louisiana) 14 April 02 Don't get bitten by poisonous snakes; local antivenin stocks outdated (Kimberly Krupa)
Snakebite treatment should be supportive until envenoming is suspected from the clinical signs. Specific treatment involves administration of antivenin, said Hutchinson.
Russell LaMontagne, a spokesman for Savage Laboratories, the New York company the produces CroFab, attributed the medicine shortage to a "problem with one company who is in charge of one of the manufacturing steps."
The U.S. Food and Drug Administration singled out the company that does the filling and freeze-drying of CroFab because inaccuracies ruined an entire batch of medicine, he said. The FDA put a three-month delay on production.
"This is happening because this is a new product, and in any new product there are going to be kinks in the process," said LaMontagne.
Asked if CroFab would be available to hospitals across the country by early June, as predicted several weeks ago, LaMontagne said, "at the earliest, we hope. But we still don't know."
In a news release sent to hospitals last month, Protherics and Savage Laboratories said "it is possible there will be no CroFab available to the United States this snakebite season."
The snakebite season is April to October, when outdoor activities are most popular.
The shortage also has been caused by an unexpected demand for CroFab, which entered the market October 2000, said LaMontagne.
"When we came out with this, we didn't assume we would be supplying all the hospitals in the country," he said.
But when CroFab became popular in U.S. hospitals, Wyeth-Ayerst Laboratories soon announced it would stop producing its 50-year-old polyvalent antivenin, for years the principal medicine used to treat snakebites.
Wyeth's antivenin was made from horse serum, which caused allergic reactions in some people. Part of CroFab's popularity came from the fact that it is less likely to cause serum sickness, allowing physicians to care for patients who would normally not be treated, said LaMontagne.
CroFab is administered to patients through a series of injections. The average patient receives four to six doses per snakebite.
ARIZONA DAILY STAR (Tucson) 17 April 02 Big rattler bites girl, 4; she seems OK (Thomas Stauffer)
Since 1954, doctors have treated snakebites with an antivenin derived from horse blood commonly known as Wyeth Serum. While effective in neutralizing snake venom, Wyeth Serum carries several proteins that can cause serious side effects, Sullivan said.
"Wyeth used an old purification process that didn't get rid of all the extraneous proteins, and those cause what they call serum sickness, which can last for a couple of days," he said.
Serum sickness can even be life-threatening for people very sensitive to antivenin, Sullivan said.
Sullivan and Dr. Findlay Russell of the UA started working on a different purification process about 18 years ago. Protherics Inc. paid Sullivan and Russell royalties and developed CroFab, which was approved for use by the Food and Drug Administration (news - web sites) in October 2000. The company began manufacturing the antivenin a year later.
The improved purification process invented by Sullivan and Russell resulted in an antivenin that is not only much less allergenic than Wyeth Serum but does a better job of targeting snake venom in the body and neutralizing it, Iserson said.
In late March, Protherics released a statement to hospitals that shipments of CroFab would be delayed for two months due to a problem in freeze-drying the antivenin, Mellor said.
"They said they should be releasing more by June, but that the process could take longer," she said.
Meanwhile, the company that had produced Wyeth Serum won't ship the drug in May or June, Mellor said.
The company may have stopped producing Wyeth Serum for economic reasons due to the emergence of CroFab as the drug of choice for snakebites, Mellor said.
NORTH COUNTY TIMES (Escondido, California) 28 April 02 Local hospitals out of antivenom (Henri Brickey)
And veterinarians get a special stock of the serum specially bottled for animals, which is still available and cheaper than Cro Fab. The veterinary serum is created specifically for animals by Fort Dodge Laboratories Inc., a division of Wyeth-Ayerst Laboratories, makers of the human Antivenin.
ODESSA AMERICAN (Texas) 21 June 02 Shortage of antivenin could end by next week (David J. Lee)
“Wyeth, the makers of Antivenin, which until last year was the only snakebite antivenom available in the United States, has apparently left the market,” said Russell Lamontagne, Savage Labs public information officer. “When Crofab was launched last year Savage did not anticipate having to supply the entire market. Crofab is a complex biotechnology product that takes up to two years to produce.”
NATIONAL POST (Toronto, Ontario) 13 August 02 Cottage country rattled by spate of snake bites - Doctors warn of shortage of medicine (Odile Nelson)
The ministry used to run a provincial antivenin depot from which it distributed a Canadian-made medicine to area hospitals on a case-by-case basis. But last summer Wyeth-Ayerst Canada stopped producing the medicine, so the ministry began buying a more expensive brand from the United States.
ODESSA AMERICAN (Texas) 02 November 02 Snakebite treatment shortage finally over (Aaron Bensonhaver)
Wyeth, who used to be the top producer of snakebite serums, pulled out of the market unexpectedly in late 2000. CroFab batches take about two years to produce, so when Wyeth disappeared, the weight put on Savage Labs was very heavy, LaMontagne said.
SAN FRANCISCO CHRONICLE (California) 14 February 01 First The Rattle, Then The Fangs - But do not fear, there's a new snakebite treatment (Paul McHugh)
Wyeth, a division of American Home Products Corporation, has announced it intends to gently withdraw from the antivenin market. This year, it will focus on producing a five-year supply of rattlesnake antivenin, and a five-year supply of coral snake antivenin.
At the end of 2001, it will discontinue the antivenin operation, leaving it for other firms to adopt the public service role.
Sales of antivenin are relatively small; it has never been a highly profitable product for Wyeth. Protherics, however, can look for an initial rush of sales, as stocks are replaced with CroFab.
LOS ANGELES TIMES (California) 12 May 01 Rattlers Aplenty, but Snakebite Serum Is Scarce - As the reptiles wake from hibernation, the makers of antivenin announce they've sold out of treatment. Area hospitals are in short supply. (Noaki Schwartz)
In the meantime, Wyeth said it expects to have a very limited supply of its serum available in July “on an emergency basis only” and will stop production of antivenin entirely by the end of the year. Doug Petkus, a spokesman for Wyeth-Ayerst, said the company's decision was “based on a review of manufacturing capacity and human resource issues,” not economic concerns.
SACRAMENTO BEE (California) 05 July 01 Year of the snake: Lots of rattler activity, with busy months yet to come (Gwendolyn Crump)
Wyeth-Ayerst stopped production of its Antivenin Polyvalent last fall after what the company called an FDA “inspection issue.” It committed to make a year's worth of its antivenom before stopping production.
Doug Petkus, a spokesman for Wyeth-Ayerst, said the decision was based on a review of manufacturing capacity and resource issues.
“We felt the market was (prepared) for our exit,” Petkus said.
ABC NEWS (USA) 07 August 00 Snake-Bite Crisis
Steven Pike, medical director of emergency services at Tucson's St. Joseph's Hospital, said that if the hospital doesn't get a resupply soon, area hospitals may have to develop some sort of rationing system for the drug.
The shortage is being blamed on the drug's only manufacturer, Wyeth-Ayerst.
The Pennsylvania-based company was forced to close its plant for renovations this summer after sterilization problems were discovered by federal inspectors, company officials have said.
Wyeth stopped all production of antivenin last month, and no more will be produced until early next year. Until then, the company will supply the drug on an emergency basis only.